Pregnancy outcome following use of levodopa, pramipexole, ropinirole, and rotigotine for restless legs syndrome during pregnancy: a case series

• DOI: 10.1111/ene.12001
• Publication Date: 2012-10-22T08:21:16Z
• Authors: M. Dostal; C. Weber‐Schoendo...; J. Sobesky; C. Schaefer
• Keywords: Ropinirole; Pramipexole; Rotigotine; Cabergoline; Restless Legs Syndrome

Background Restless legs syndrome ( RLS ) is related to parity, and its symptoms may worsen during pregnancy. Treatment with levodopa or dopamine agonists the first‐line therapy for ; however, there are limited data on treatment in We therefore assessed safety of levodopa, pramipexole, rotigotine, ropinirole Methods Prospective documentation pregnancies exposed between 1998 2011 was evaluated as their outcome (teratogenicity fetotoxicity) by B erlin I nstitute C linical T eratology D rug R isk A ssessment P regnancy. Results were able complete 59 pregnancy outcomes pharmacotherapy. For specific treatments, numbers pregnancies/live born children/spontaneous abortions/induced abortions/malformations follows: only: 38/29 (one pair twins)/3/7/3; pramipexole 12/9/3/0/0; rotigotine 2/2/0/0/0; 3/2/0/1/0; combined pramipexole: 3/3/0/0/0; ropinirole: 1/1/0/0/0. No major birth defects found any treatment, three infants had minor anomalies. Conclusions In our small prospective case series, no increased risk above baseline malformations other adverse pramipexole. If necessary, be considered an alternative cabergoline, which has been well documented